What do systematic reviews say?

Low‐dose colchicine vs placebo

• Colchicine for acute gout 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 133 participants
  GRADE not reported

Summary of findings table ‐ Intraperitoneal local anaesthetic vs control

It is very uncertain whether summary of findings table ‐ Intraperitoneal local anaesthetic changes serious adverse events compared with control (very low certainty).

• Intraperitoneal local anaesthetic instillation versus no intraperitoneal local anaesthetic instillation for… 2021 · Cochrane Headline outcomes only
  RR 1.07 [0.49, 2.34]
  13 studies · 988 participants
  Very low

Phentermine/topiramate vs placebo

Phentermine/topiramate showed no clear difference in serious adverse events compared with placebo (low certainty).

• Long‐term effects of weight‐reducing drugs in people with hypertension 2021 · Cochrane Headline outcomes only
  RR 0.85 [0.49, 1.48]
  1 study · 1305 participants
  Low

Naltrexone/bupropion vs placebo

Naltrexone/bupropion showed no clear difference in serious adverse events compared with placebo (moderate certainty).

• Long‐term effects of weight‐reducing drugs in people with hypertension 2021 · Cochrane Headline outcomes only
  RR 1.05 [0.96, 1.14]
  1 study · 8283 participants
  Moderate

Orlistat vs placebo

Orlistat probably leads to higher serious adverse events compared with placebo (moderate certainty).

• Long‐term effects of weight‐reducing drugs in people with hypertension 2021 · Cochrane Headline outcomes only
  RR 1.45 [1.1, 1.91]
  3 studies · 1476 participants
  Moderate

Intervention not reported

It is very uncertain whether the intervention changes serious adverse events (very low certainty).

• Topical microbicides for preventing sexually transmitted infections 2021 · Cochrane Headline outcomes only
  RR 1 [0.81, 1.24]
  3 studies · 4958 participants
  Very low

Intervention not reported

The intervention showed no clear difference in serious adverse events (low certainty).

• Topical microbicides for preventing sexually transmitted infections 2021 · Cochrane Headline outcomes only
  RR 1.25 [0.87, 1.79]
  2 studies · 3069 participants
  Low

Intervention not reported

The intervention showed no clear difference in serious adverse events (low certainty).

• Topical microbicides for preventing sexually transmitted infections 2021 · Cochrane Headline outcomes only
  RR 1.12 [0.94, 1.32]
  2 studies · 4588 participants
  Low

Any dose of lacosamide vs placebo

Any dose of lacosamide probably leads to higher serious adverse events compared with placebo (moderate certainty).

• Lacosamide add‐on therapy for focal epilepsy 2021 · Cochrane Headline outcomes only
  RR 1.53
  5 studies · 2199 participants
  Moderate

Vitamin D vs placebo or no intervention

• Vitamin D supplementation for chronic liver diseases in adults 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Circumcision devices vs standard surgical techniques

• Circumcision devices versus standard surgical techniques in adolescent and adult male circumcisions 2021 · Cochrane Headline outcomes only
  no estimate extracted
  11 studies · 3472 participants
  Moderate

Degarelix vs standard androgen suppression therapy

Degarelix showed no clear difference in serious adverse events compared with standard androgen suppression therapy (low certainty).

• Degarelix for treating advanced hormone‐sensitive prostate cancer 2021 · Cochrane Headline outcomes only
  RR 0.8 [0.62, 1.05]
  9 studies · 2750 participants
  Low

Adjuvant chemotherapy vs no chemotherapy

It is very uncertain whether adjuvant chemotherapy changes serious adverse events compared with no chemotherapy (very low certainty).

• Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma 2021 · Cochrane Headline outcomes only
  RR 17.82 [2.43, 130.82]
  1 study · 219 participants
  Very low

Adjuvant S‐1 vs gemcitabine

• Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 70 participants
  Very low

Anti‐IL13 or anti‐IL4 agents vs placebo

Anti‐IL13 or anti‐IL4 agents showed no clear difference in serious adverse events compared with placebo (moderate certainty).

• Anti‐interleukin‐13 and anti‐interleukin‐4 agents versus placebo, anti‐interleukin‐5 or anti‐immunoglobulin‐E agents,… 2021 · Cochrane Headline outcomes only
  OR 0.91 [0.76, 1.09]
  22 studies · 7739 participants
  Moderate

Urtoxazumab (3.0 mg/kg) vs placebo

Urtoxazumab (3.0 mg/kg) may leads to lower adverse events ‐ serious compared with placebo (low certainty).

• Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 71 participants
  Low

Urtoxazumab (1.0 mg/kg) vs placebo

• Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 74 participants
  Low

Continuous positive airway pressure (CPAP) vs phosphodiesterase type 5 inhibitors

• Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 40 participants
  Very low

Continuous positive airway pressure (CPAP) vs no CPAP

• Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 27 participants
  Very low

Continuous positive airway pressure (CPAP) vs sham CPAP

The review found no eligible studies for this question.

• Non‐invasive positive airway pressure therapy for improving erectile dysfunction in men with obstructive sleep apnoea 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found